Stock Research: Laboratorios Farmaceuticos Rovi

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Laboratorios Farmaceuticos Rovi

BME:ROVI ES0157261019
60
  • Value
    86
  • Growth
    27
  • Safety
    Safety
    23
  • Combined
    46
  • Sentiment
    77
  • 360° View
    360° View
    60
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spanish pharmaceutical company focused on the development and commercialization of medicines and drugs. It operates in Diagnostics (contrast mediums), Prescription (Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi, Absorcol), and Over The Counter (Perspirex, Enerzona, Dentimelo, ColdPack) fields. ROVI operates nationwide and abroad, with subsidiaries including Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL, and Bertex Pharma GmbH. In the last fiscal year, the company had 2179 employees, a market cap of $3215 million, profits of $495 million, and revenue of $791 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 60 (better than 60% compared with alternatives), overall professional sentiment and financial characteristics for the stock Laboratorios Farmaceuticos Rovi are above average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Laboratorios Farmaceuticos Rovi. The consolidated Sentiment Rank has a good rank of 77, which means that professional investors are more optimistic about the stock than for 77% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 86 or better than 86% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 23, meaning that the share price of Laboratorios Farmaceuticos Rovi is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 27. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
23 24 35 42
Growth
27 6 19 95
Safety
Safety
86 93 88 75
Sentiment
77 16 98 46
360° View
360° View
60 15 76 80
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
57 47 70 81
Opinions Change
50 12 69 50
Pro Holdings
n/a 32 90 12
Market Pulse
83 43 83 53
Sentiment
77 16 98 46
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
23 24 35 42
Growth
27 6 19 95
Safety Safety
86 93 88 75
Combined
46 43 38 92
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
37 40 38 49
Price vs. Earnings (P/E)
26 26 33 40
Price vs. Book (P/B)
18 19 22 17
Dividend Yield
54 58 63 72
Value
23 24 35 42
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
73 12 4 74
Profit Growth
23 12 18 92
Capital Growth
30 26 19 31
Stock Returns
19 24 98 96
Growth
27 6 19 95
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
78 80 76 57
Refinancing
45 44 47 42
Liquidity
89 95 100 76
Safety Safety
86 93 88 75

Similar Stocks

Discover high‑ranked alternatives to Laboratorios Farmaceuticos Rovi and broaden your portfolio horizons.

thyssenkrupp

XTRA:TKA
Country: Germany
Industry: Steel
Size: X-Large
Full Stock Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Polski Koncern Naftowy ORLEN Spolka Akcyjna

WSE:PKN
Country: Poland
Industry: Oil & Gas Refining
Size: X-Large
Full Stock Analysis

Infineon

XTRA:IFX
Country: Germany
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.